The pathogenesis of psoriasis can be explained by dysregulation of immunological cell
function as well as keratinocyte proliferation/differentiation. Recently, the immunological …

TNF was originally described as a circulating factor that can cause necrosis of tumours, but
has since been identified as a key regulator of the inflammatory response. This review …

European S3-Guidelines on the systemic treatment of psoriasis vulgaris D Pathirana, AD
Ormerod, P Saiag, C Smith, PI Spuls, A Na Page 1 JEADV october 2009, volume 23 …

Background Inflammatory cytokines such as tumor necrosis factor (TNF) have been
implicated in the pathogenesis of psoriasis. We evaluated the safety and efficacy of …

Background Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the
treatment of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which …

Objective Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was
evaluated for its safety and efficacy compared with placebo in the treatment of active …

The strong societal urge to reduce the use of experimental animals, and the biological
differences between rodent and human skin, have led to the development of alternative …

Objective Etanercept has been shown to improve the articular and cutaneous manifestations
of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect on …

Background Currently available treatments for moderate to severe psoriasis are either
incompletely effective in some patients, or are associated with toxic effects. Since tumour …

Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence
of psoriasis in Western industrialized countries ranges from 1.5% to 2%. Patients afflicted …